Amid new worries that legal copycats of the weight-loss drugs from Eli Lilly and Novo Nordisk could erode the market for the branded drugs, Lilly on Wednesday said it would sell a version of Zepbound through the telemedicine company Ro.

Eli Lilly (LLY) has added a new telehealth partner to expand access to single-dose vials of its blockbuster weight loss drug Zepbound. Ro is joining other telehealth platforms and Amazon Pharmacy (AMZN) in giving patients access to Lilly's top GLP-1 product by plugging in to the pharmaceutical giant's new direct-to-consumer platform,

It is made possible through a first-of-a-kind integration with Eli Lilly’s direct-to-consumer website, and aims to streamline access to the popular treatment.